Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 6/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 6/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250310 | 1.00 | PTPN7 (0.47) | PTPN7DUSP3ARNR3C2KIF11 | |
| SCHEMBL3637724 | 0.86 | KIF11 (0.51) | KIF11P2RX7DAO | |
| SCHEMBL6858263 | 0.86 | RXRA (0.47) | PTPN7DUSP3ARKIF11DAO | |
| SCHEMBL1568951 | 0.84 | NR3C2 (0.46) | PTPN7DUSP3ARNR3C2KIF11 | |
| SCHEMBL13284215 | 0.83 | XDH (0.44) | PTPN7DUSP3ARNR3C2KIF11 | |
| SCHEMBL41768 | 0.80 | PTPN7 (0.45) | PTPN7DUSP3ARNR3C2KIF11 | |
| SCHEMBL2642102 | 0.80 | AR (0.48) | PTPN7DUSP3ARNR3C2KIF11 | |
| SCHEMBL10662203 | 0.79 | PTPN7 (0.47) | PTPN7DUSP3ARNR3C2KIF11 | |
| SCHEMBL12106845 | 0.79 | DAO (0.39) | KIF11DAO | |
| SCHEMBL7861160 | 0.79 | MAPT (0.39) | PTPN7DUSP3KIF11EPHX1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | PTPN7 3161/4885DUSP3 2166/4885AR 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.